Τίτλος:
Authors' Response to the Letter by Lamarca et al. Entitled "temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration" Regarding "activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms"
Συγγραφείς:
Chatzellis, E.
Daskalakis, K.
Angelousi, A.
Tsoli, M.
Alexandraki, K.I.
Wachula, E.
Meirovitz, A.
Maimon, O.
Grozinsky-Glasberg, S.
Gross, D.
Kos-Kudła, B.
Koumarianou, A.
Kaltsas, G.
Λέξεις-κλειδιά:
capecitabine; temozolomide; capecitabine; dacarbazine; temozolomide, advanced cancer; bone marrow suppression; cancer chemotherapy; cancer control; comorbidity; drug activity; drug safety; follow up; functional status; human; Letter; maintenance therapy; neuroendocrine tumor; pancreas islet cell tumor; priority journal; progression free survival; treatment duration; treatment response; tumor growth; neuroendocrine tumor; treatment duration, Capecitabine; Dacarbazine; Duration of Therapy; Humans; Neuroendocrine Tumors; Temozolomide
